Nederlands Neonataal Netwerk (N3), the Netherlands Report issue

Academic/Hospital Phase 3

Organization Overview

First Clinical Trial
2020
NCT04430790
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Nederlands Neonataal Netwerk (N3), the Netherlands | NETwerk, Belgium

Active Ingredients

Drugs in Phase 3 Trials (2)

18f-alf-nota-octreotide (1 trial)

doxapram (dopram) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Neuroendocrine Tumors (Phase 3)

Pulmonary Valve Insufficiency (Phase 3)

Respiratory Insufficiency (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 2